Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faes Farma, S.A.
• Treatments: Cetirizine; Levocetirizine

Criteria

Inclusion Criteria:

• 18 to 70 years old.

• Documented history of CIU for at least 6 weeks prior to entry in the study.

Exclusion Criteria:

• Dermatological pathology other than chronic idiopathic urticaria.

• History of autoimmune disorders, Hodgkin's disease, lymphoma, leukemia and generalized cancer.

• Pregnant or breast-feeding women.

• Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.

• Patients who have a recent history (within previous 12 months) of drug addiction or alcohol abuse.

• Patients who are currently participating in or have participated in another clinical trial within the last 3 months